The Food and Drug Administration announced the approval of AstraZeneca’s (AZN) Koselugo for adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. The FDA previously approved Koselugo capsules and granules for pediatric patients one year of age and older for this indication.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca approves AstraZeneca’s Koselugo for adults with NF1
- Genprex adds Gabrail Cancer Center for Acclaim clinical trials 1 and 3
- Mangoceuticals Stock (MGRX) Soars on Deal to Sell Obesity Drugs for Eli Lilly, Novo Nordisk
- FDA appoints Richard Pazdur as Director of CDER
- AstraZeneca Stock (AZN) Hits 1-Year High — Here’s Why